Literature DB >> 18703348

Differences in amniotic fluid and maternal serum cytokine levels in early midtrimester women without evidence of infection.

Sharon S W Chow1, Maria E Craig, Cheryl A Jones, Beverley Hall, Jacki Catteau, Andrew R Lloyd, William D Rawlinson.   

Abstract

The amniotic fluid cytokine profile has been shown to be indicative of various disease states, and changes may be associated with preterm labor or infection. Anti-inflammatory cytokine profiles may be essential for successful normal pregnancy. However, there are currently few normative data on the concentration of cytokines in amniotic fluids during pregnancy. The aim of this study was to provide new amniotic fluid cytokine data for future comparative studies in disease states, notably in utero viral infections, and to compare these with maternal serum levels. Amniotic fluid was obtained from 100 pregnant women undergoing elective amniocentesis at the Royal Hospital for Women, Randwick. Concentrations of 27 cytokines were simultaneously measured in amniotic fluid and a subset of matching maternal sera (n=33) using a multiplex bead-based immunoassay system (Bio-Plex, Bio-Rad). To exclude infection, nested multiplex PCR targeting 17 known congenital infectious agents were performed on all amniotic fluid and maternal serum samples, and serological testing was also performed against some of these agents. Maternal serum concentration was positively correlated with amniotic fluid levels for MIP-1beta (r=0.39, P=0.027). IL-1ra was positively correlated to maternal age (r=0.210, P=0.036), and mean IL-5 levels were significantly higher in amniotic fluids from pregnancies with male fetuses than those with female fetuses (P=0.036). Normal amniotic fluid concentrations for five cytokines (IL-6, IL-8, IP-10, MCP-1, IL-1ra) were found to be significantly elevated over maternal serum concentrations in matched pairs (P<0.05). Concentrations of 12 cytokines (eotaxin, IFN-gamma, IL-9, IL-12, IL-15, IL-17, MIP-1alpha, MIP-1beta, RANTES, TNF-alpha, VEGF, PDGF bb) were significantly elevated in maternal serum compared to paired amniotic fluid at midtrimester (P<0.05). Amniotic fluid may be more representative of the fetal cytokine profile than cytokine analysis on antenatal sera as it represents predominantly fetal urinary and respiratory secretions. This study provides new normative data for multiple cytokine levels in amniotic fluid and maternal sera at 14-16 weeks gestation, and is a valuable tool for future diagnostic and comparative studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703348     DOI: 10.1016/j.cyto.2008.06.009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  30 in total

1.  Normal early pregnancy: a transient state of epigenetic change favoring hypomethylation.

Authors:  Wendy M White; Brian C Brost; Zhifu Sun; Carl Rose; Iasmina Craici; Steven J Wagner; Stephen Turner; Vesna D Garovic
Journal:  Epigenetics       Date:  2012-07-01       Impact factor: 4.528

2.  The antibiotic treatment of PPROM study: systemic maternal and fetal markers and perinatal outcomes.

Authors:  Brian M Mercer; Dennis T Crouse; Robert L Goldenberg; Menachem Miodovnik; Delicia C Mapp; Paul J Meis; Mitchell P Dombrowski
Journal:  Am J Obstet Gynecol       Date:  2011-09-08       Impact factor: 8.661

3.  IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.

Authors:  Sarah Y Lee; Irina A Buhimschi; Antonette T Dulay; Unzila A Ali; Guomao Zhao; Sonya S Abdel-Razeq; Mert O Bahtiyar; Stephen F Thung; Edmund F Funai; Catalin S Buhimschi
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

4.  Maternal Gestational Immune Response and Autism Spectrum Disorder Phenotypes at 7 Years of Age in the Seychelles Child Development Study.

Authors:  Jessica L Irwin; Alison J Yeates; Maria S Mulhern; Emeir M McSorley; J J Strain; Gene E Watson; Katherine Grzesik; Sally W Thurston; Tanzy M Love; Tristram H Smith; Daniel W Mruzek; Conrad F Shamlaye; Catriona Monthy; Gary J Myers; Philip W Davidson; Edwin van Wijngaarden
Journal:  Mol Neurobiol       Date:  2018-11-14       Impact factor: 5.590

Review 5.  Host-Intrinsic Interferon Status in Infection and Immunity.

Authors:  Beiyun C Liu; Joseph Sarhan; Alexander Poltorak
Journal:  Trends Mol Med       Date:  2018-07-07       Impact factor: 11.951

6.  Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery.

Authors:  Maria-Teresa Gervasi; Roberto Romero; Gabriella Bracalente; Offer Erez; Zhong Dong; Sonia S Hassan; Lami Yeo; Bo Hyun Yoon; Tinnakorn Chaiworapongsa
Journal:  J Perinat Med       Date:  2012-06       Impact factor: 1.901

7.  Pre-B cell colony enhancing factor (PBEF/NAMPT/Visfatin) and vascular endothelial growth factor (VEGF) cooperate to increase the permeability of the human placental amnion.

Authors:  J M Astern; A C Collier; C E Kendal-Wright
Journal:  Placenta       Date:  2012-11-12       Impact factor: 3.481

8.  Alpha-lipoic acid inhibits tumor necrosis factor-induced remodeling and weakening of human fetal membranes.

Authors:  Robert M Moore; Jillian B Novak; Deepak Kumar; Joseph M Mansour; Brian M Mercer; John J Moore
Journal:  Biol Reprod       Date:  2008-12-23       Impact factor: 4.285

9.  Fetal sex is associated with maternal stimulated cytokine production, but not serum cytokine levels, in human pregnancy.

Authors:  Amanda M Mitchell; Marilly Palettas; Lisa M Christian
Journal:  Brain Behav Immun       Date:  2016-06-29       Impact factor: 7.217

10.  A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset.

Authors:  Ender Altiok; Figen Aksoy; Yıldız Perk; Fulya Taylan; Peter W Kim; Barbaros Ilıkkan; Gülten Turkkani Asal; Raphaela Goldbach-Mansky; Ozden Sanal
Journal:  Clin Immunol       Date:  2012-08-16       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.